<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">IJPharm</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0253-7613</issn>
      <issn pub-type="epub">1998-3751</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24550599</article-id>
      <article-id pub-id-type="pmc">3912797</article-id>
      <article-id pub-id-type="publisher-id">IJPharm-46-123</article-id>
      <article-id pub-id-type="doi">10.4103/0253-7613.125194</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Drug Watch</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Clopidogrel: A possible exacerbating factor for psoriasis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Mahajan</surname>
            <given-names>Vikram K.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Khatri</surname>
            <given-names>Gayatri</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Prabha</surname>
            <given-names>Neel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abhinav</surname>
            <given-names>C.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sharma</surname>
            <given-names>Vikas</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Dermatology, Venereology &amp; Leprosy, Dr. R. P. Govt. Medical College, Kangra (Tanda) - 176001, Himachal Pradesh, India</aff>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence to:</bold> Dr. Vikram K. Mahajan, E-mail: <email xlink:href="vkm1@rediffmail.com">vkm1@rediffmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2014</year>
      </pub-date>
      <volume>46</volume>
      <issue>1</issue>
      <fpage>123</fpage>
      <lpage>124</lpage>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>4</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>10</day>
          <month>5</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>11</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Pharmacology</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A 64-year-old man developed palmoplantar pustulosis eventuating into palmoplantar pustular psoriasis following treatment with diltiazem, atenolol, aspirin and atorvastatin for suspected coronary artery disease (CAD). Treatment for psoriasis, stopping atenolol and substituting aspirin with clopidogrel did not benefit. Subsequently, he stopped all his drugs and did not develop psoriasis or symptoms/signs of CAD. Re-challenge with oral clopidogrel precipitated his skin lesions. This case has implications for patients having psoriasis and cardiovascular comorbidity where clopidogrel/ticlopidine or aspirin may not be a useful alternative.</p>
      </abstract>
      <kwd-group>
        <title>KEY WORDS</title>
        <kwd>Adverse drug reactions</kwd>
        <kwd>antiplatelet therapy</kwd>
        <kwd>clopidogrel</kwd>
        <kwd>psoriasis triggers</kwd>
        <kwd>pustular psoriasis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1-1">
      <title>Introduction</title>
      <p>The exogenous factors that trigger psoriasis or induce flare-ups are poorly understood. Physical trauma (Koebner&#x2019;sphenomenon), infections (bacterial, viral and yeast), metabolic disorders (primary or secondary hypocalcemia), smoking, alcohol abuse and drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), antimalarials, betablockers, angiotensin-converting enzyme antagonists (candesartan), lithium, gemfibrozil, imiquimod, interferon-&#x3B1; (IFN-&#x3B1;), IFN-&#x3B3;, and withdrawal of corticosteroids or cyclosporine have been frequently implicated for exacerbation of psoriasis.[<xref rid="ref1" ref-type="bibr">1</xref>] We describe a case of palmoplantar pustular psoriatic eruptions which were exacerbated and perpetuated by clopidogrel in a patient suspected of coronary artery disease (CAD).</p>
    </sec>
    <sec id="sec1-2">
      <title>Case Report</title>
      <p>This 64-year-old human immunodeficiency virus-negative, non-smoker and non-alcoholic male patient presented with pustular psoriasis involving both palms and soles for the past &gt;2years with waxing and waning clinical course. There was no personal or family history of psoriasis previously. Historically, he had developed acrodermatitis continua of Hallapeu-like skin lesions 7-8 months after taking treatment for a clinically suspected CAD despite having a normal electorcardiogram, echocardiography and treadmill test. Patient was taking diltiazem (75 mg/d), atenolol (50 mg/d), aspirin (75 mg/d) and atorvastatin (10 mg/d). Since both the drugs are known to precipitate/aggravate psoriasis atenolol and aspirin were stopped and clopidogrel 75 mg/d was prescribed by his physician. However, his skin lesions progressed relentlessly eventuating into palmoplantar psoriasis with pustulosis [<xref ref-type="fig" rid="F1">Figure 1</xref>]. A skin biopsy from a pustular lesion showed hyperkeratosis, parakeratosis, acanthosis, papillomatosis and papillary neutrophilic collection suggestive of psoriasis having pustular differentiation [<xref ref-type="fig" rid="F2">Figure 2</xref>]. He did not improve with topical emollients, tar and corticosteroid ointments and developed intolerable retching/vomiting after systemic methotrexate (15 mg/week). Although he continued with topical treatment, his skin lesions did not remit. However, his skin lesions disappeared completely within a month when he stopped all medications which were for CAD without his physician's advice. He did not develop any skin lesions after restarting diltiazem and atorvastatin on the insistence of his physician but these returned within a week after taking clopidogrel (75 mg/d) re-challenge (performed with his consent). Since then he has stopped all his drugs on his own and is free of psoriasis and has not developed any symptoms/signs of CAD.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Chronic plaque psoriasis over left palm and right sole that has evolved from palmoplantar pustulosis (a) note plantar pustulosis lesions (b) similar lesions were present over other palm/sole</p>
        </caption>
        <graphic xlink:href="IJPharm-46-123-g001"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Histopathology of a plantar lesion showing hyperkeratosis, parakeratosis, acanthosis, papillomatosis and neutrophils in dermal papillae (inset) (H and E, &#xD7;10, Inset, &#xD7;40)</p>
        </caption>
        <graphic xlink:href="IJPharm-46-123-g002"/>
      </fig>
    </sec>
    <sec sec-type="discussion" id="sec1-3">
      <title>Discussion</title>
      <p>Clopidogrel, a thienopyridine derivative, is metabolized to its active metabolite by cytochrome P450 and irreversibly inhibits the platelet aggregation induced by adenosine diphosphate by inhibiting P2Y<sub>12</sub> receptor.[<xref rid="ref2" ref-type="bibr">2</xref>] Despite clinical concerns for its possible interaction with omeprazole, clopidogrel is considered to be a safe and effective medication for prevention of vascular events in patients with cerebrovascular or cardiovascular diseases associated with risk of thromboembolic events.[<xref rid="ref3" ref-type="bibr">3</xref>] It is as effective as ticlopidine or aspirin but its combination with aspirin is presumed to be more effective than either agent alone.[<xref rid="ref4" ref-type="bibr">4</xref>] Nausea, vomiting, diarrhea, abdominal discomfort and gastrointestinal bleeding, which may get aggravated with simultaneous use of NSAIDs, are its common adverse effects. Neutropenia and thrombotic thrombocytopenic purpura are rare but serious adverse effects.[<xref rid="ref3" ref-type="bibr">3</xref>] Whereas severe skin hypersensitivity maculopapular rash, pruritus, fixed drug eruptions, urticaria and angioedema are not uncommon cutaneous adverse effects, suberythrodermic pustular psoriasis induced by clopidogrel is extremely rare.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] Ticlopidine, another thienopyridine derivative, have similar pharmacological and adverse drug reactions profile. Initially, more common drugs like aspirin and atenolol were suspected to exacerbate/perpetuate psoriasis in our patient. However, he continued to have skin lesions long after these drugs were stopped. It is only when all the drugs including clopidogrel were stopped, the patient became free of skin lesions indicating the offending drug. We did not perform re-challenge with aspirin and atenolol (well-known to exacerbate psoriasis) and oral provocation test imputed his psoriasis lesions to clopidogrel. The causality as assessed by the World Health Organization Uppsala Monitoring Centre causality scale was certain in view of temporal relationship to drug intake, complete clearance and no recurrence of skin lesions after drug withdrawal (de-challenge) and recurrence after re-challenge.[<xref rid="ref8" ref-type="bibr">8</xref>]</p>
      <p>We report this case to highlight an uncommon side effect of a very commonly used drug that can have serious implications for psoriasis patients with cardiovascular comorbidities. Clopidogrel, ticlopidine or aspirin may not be useful alternatives here. Dipyridamole, another platelet aggregation inhibitor, which improves blood and oxygen circulation to the myocardium by inducing maximum dilatation of coronary vessels and enhances development of collateral vessels, can be a possible alternative. It is advisable to limit the use of clopidogrel/ticlopidine for pharmacotherapy to reduce the risk of death from thromboembolic events in patients of recent myocardial infarction or stroke rather than using it as prophylaxis or as an alternative to anticoagulants such as warfarin.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nil</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict of Interest:</bold> No</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawamura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ochiai</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Candesartan cilexetil induced pustular psoriasis</article-title>
          <source>Eur J Dermatol</source>
          <year>2003</year>
          <volume>13</volume>
          <fpage>406</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">12948927</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Majerus</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Tollfsen</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Brunton</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Lazo</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>KL</given-names>
            </name>
          </person-group>
          <article-title>Blood coagulation and anticoagulants, thrombolytic, andantiplateletdrugs: Antiplatelet drugs</article-title>
          <source>Goodman Gilman's the Pharmacological Basis of Therapeutics</source>
          <year>2006</year>
          <edition>11th ed</edition>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>McGraw-Hill Medical Publishing Division</publisher-name>
          <fpage>1481</fpage>
          <lpage>4</lpage>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Depta</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Bhatt</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Omeprazole and clopidogrel: Should clinicians be worried?</article-title>
          <source>Cleve Clin J Med</source>
          <year>2010</year>
          <volume>77</volume>
          <fpage>113</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">20124268</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Chrolavicius</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tognoni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>KK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation</article-title>
          <source>N Engl J Med</source>
          <year>2001</year>
          <volume>345</volume>
          <fpage>494</fpage>
          <lpage>502</lpage>
          <pub-id pub-id-type="pmid">11519503</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gowda</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Misra</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>IA</given-names>
            </name>
          </person-group>
          <article-title>Hypersensitivity skin rash: An adverse drug reaction to clopidogrel loading dose</article-title>
          <source>Int J Cardiol</source>
          <year>2004</year>
          <volume>95</volume>
          <fpage>333</fpage>
          <pub-id pub-id-type="pmid">15193841</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Worm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Groneberg</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Clopidogrel-associated angioedema</article-title>
          <source>Am J Med</source>
          <year>2003</year>
          <volume>114</volume>
          <fpage>77</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">12543298</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meissner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Beier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wolter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gille</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Suberythrodermic pustular psoriasis induced by clopidogrel</article-title>
          <source>Br J Dermatol</source>
          <year>2006</year>
          <volume>155</volume>
          <fpage>630</fpage>
          <lpage>1</lpage>
          <pub-id pub-id-type="pmid">16911296</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meyboom</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Hekster</surname>
              <given-names>YA</given-names>
            </name>
            <name>
              <surname>Egberts</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Gribnau</surname>
              <given-names>FW</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>IR</given-names>
            </name>
          </person-group>
          <article-title>Causal or casual? The role of causality assessment in pharmacovigilance</article-title>
          <source>Drug Saf</source>
          <year>1997</year>
          <volume>17</volume>
          <fpage>374</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="pmid">9429837</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
